Involvement of Matrix Metalloproteinases and Association With the Expression of Human Papillomavirus in Dysplasias and Cancers of the Cervix
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Papillomavirus Infections
- Sponsor
- University Hospital, Bordeaux
- Enrollment
- 216
- Primary Endpoint
- Immunohistochemical score of expressions of matrix metalloproteinases inhibitors
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.
Detailed Description
Cervical cancer is the second most common cancer among European women under 45 years old. It is secondary to cervical dysplasia induced by persistent human papillomavirus infection. The involvement of matrix metalloproteinases in carcinogenesis of the cervix is real, but their expressions vary according to the published series. An association between the expression of MMPs and that of the human papillomavirus deserves to be explored, as this can have a prognostic influence in the case of gradual expression demonstrated in the development of (pre) cancerous lesions of the cervix. This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For control group:
- •Age between 20 and 65 years
- •Patients hospitalized for partial or total removal of the cervix
- •Absence of cervical lesion observed on biopsy or hysterectomy
- •Free, informed and written consent, dated and signed by the patient and the investigator (at the latest before any examination required by the study)
- •Affiliate or beneficiary of a social security scheme
- •For dysplasia and cancer group:
- •Age between 20 and 65 years
- •Cervical Intraepithelial Neoplasia or previously untreated cervical cancer
- •Free, informed and written consent, dated and signed by the patient and the investigator (at the latest before any examination required by the study)
Exclusion Criteria
- •For control group:
- •History of laser or conisation
- •Known antecedent of HIV infection
- •Congenital or acquired immunodepression
- •Long-term treatment with corticosteroids or immunosuppressants
- •Persons placed under the protection of justice
- •For dysplasia and cancer group:
- •History of laser or conisation
- •Pre-treatment of invasive cancers by radiotherapy or chemotherapy
- •Known antecedent of HIV infection
Outcomes
Primary Outcomes
Immunohistochemical score of expressions of matrix metalloproteinases inhibitors
Time Frame: At the screening
The immunohistochemical score is the modified HScore, also called Quickscore. It is calculated by multiplying the percentage of cells that are marked (from 0 to 100) by intensity (from 0 to 3). The total score is between 0 and 300. This score will be defined on normal, tumoral and stromal cells according to the analyzed tissue (normal, dysplasias or cancer)
Immunohistochemical score of expressions of matrix metalloproteinases
Time Frame: At the screening
The immunohistochemical score is the modified HScore, also called Quickscore. It is calculated by multiplying the percentage of cells that are marked (from 0 to 100) by intensity (from 0 to 3). The total score is between 0 and 300. This score will be defined on normal, tumoral and stromal cells according to the analyzed tissue (normal, dysplasias or cancer)